CANCER EPIDEMIOLOGY PROGRAM The Cancer Epidemiology program studies environmental, genetic, and molecular risks for cancer and cancer outcomes to identify priorities for public health and clinical intervention. The program has three aims: (1) Risk- Based Prevention and Early Detection: To identify opportunities for risk-based prevention and early detection of cancer; (2) Treatment, Outcomes and Survivorship: To improve cancer treatment, outcomes, and survivorship through epidemiologic and clinical research that leads to evidence-based interventions; (3) Integrative Molecular Epidemiology: To deepen understanding of cancer etiology, heterogeneity, and survivorship through integrative human molecular and histopathologic studies of precursor lesions and tumors. A major cross-cutting theme is addressing the epidemiology of health disparities. As a comprehensive cancer center in an economically, socially, and racially diverse state, CE is well-poised to address health equity. Across these aims, we use multidimensional North Carolina studies and conduct cross-program research to yield high impact findings. Members have expertise in population-based epidemiology, data linkage, pharmacoepidemiology, survey research, clinical research, screening, molecular and biomarker research, translational preclinical research, sociology, pathology, genomics, data science, computer science, and statistical and epidemiologic methods. Research resources include population-based studies of breast, colon, prostate, head and neck cancer as well as registries for breast and lung screening. Many of these studies participate in large national and international data-sharing initiatives and consortia. The Program brings value to the Center through study resources that collect exposure and outcome data, and biospecimens, a unique shared resource (Statewide Cancer Data), and expertise in epidemiologic methods. The Program is supported by UNC Lineberger?s investments in faculty recruitments, shared resources and developmental funds. The UNC Lineberger strategic plan emphasis on optimizing cancer outcomes in North Carolina has led to significant investment across population sciences and is expanding in new areas in coming years including endometrium and bladder, with sustained support for ongoing data collection in breast cancer and head and neck cancers. The CE Program consists of 33 members who are associated with 9 departments at UNC- Chapel Hill and affiliated institutions. During the last funding period, program members have published 776 cancer-related articles, 24% were inter-programmatic and 19% were intra-programmatic (34% collaborative). In 2019, our program members held grants totaling $10.0M (direct cost) in cancer-relevant extramural funding, including $5.2M (direct costs) from the NCI and $3.0M other peer-reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089819
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ma, Shaohua; Paiboonrungruan, Chorlada; Yan, Tiansheng et al. (2018) Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. Ann N Y Acad Sci 1434:164-172
Aung, Kyaw L; Fischer, Sandra E; Denroche, Robert E et al. (2018) Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin Cancer Res 24:1344-1354
Suh, Junghyun L; Watts, Brian; Stuckey, Jacob I et al. (2018) Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1. Biochemistry 57:2140-2149
Brock, William J; Beaudoin, James J; Slizgi, Jason R et al. (2018) Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease. Int J Toxicol 37:144-154
Thomas, Nancy E; Edmiston, Sharon N; Tsai, Yihsuan S et al. (2018) Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. Am J Dermatopathol :
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Hall, Marissa G; Marteau, Theresa M; Sunstein, Cass R et al. (2018) Public support for pictorial warnings on cigarette packs: an experimental study of US smokers. J Behav Med 41:398-405
Thorsson, V├ęsteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Wu, Bing; Zhang, Song; Guo, Zengli et al. (2018) RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. Immunity 49:886-898.e5
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10

Showing the most recent 10 out of 1525 publications